ROYALTY PHARMA PLC

(RPRX)
  Report
Delayed Quote. Delayed Nasdaq - 05/27 04:00:01 pm
41.27 USD   +3.15%
05/25INSIDER SELL : Royalty Pharma
MT
05/24TRANSCRIPT : Royalty Pharma plc Presents at UBS Global Healthcare Conference, May-24-2022 01:15 PM
CI
05/23INSIDER SELL : Royalty Pharma
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Royalty Pharma : UBS Adjusts Royalty Pharma PT to $48 From $52, Maintains Buy Rating

08/25/2021 | 11:23am EDT


© MT Newswires 2021
All news about ROYALTY PHARMA PLC
05/25INSIDER SELL : Royalty Pharma
MT
05/24TRANSCRIPT : Royalty Pharma plc Presents at UBS Global Healthcare Conference, May-24-2022 ..
CI
05/23INSIDER SELL : Royalty Pharma
MT
05/23INSIDER SELL : Royalty Pharma
MT
05/23Royalty Pharma to Present at the UBS Global Healthcare Conference 2022
GL
05/23Royalty Pharma to Present at the UBS Global Healthcare Conference 2022
AQ
05/18Royalty Pharma Investor Day Highlights Stronger Growth Outlook and the Power of Its Uni..
AQ
05/17Royalty pharma announces charitable alliance with mount sinai
AQ
05/17TRANSCRIPT : Royalty Pharma plc - Analyst/Investor Day
CI
05/17Royalty Pharma Sets New Capital Deployment Target
MT
More news
Analyst Recommendations on ROYALTY PHARMA PLC
More recommendations
Financials (USD)
Sales 2022 2 276 M - -
Net income 2022 847 M - -
Net Debt 2022 5 653 M - -
P/E ratio 2022 20,2x
Yield 2022 1,79%
Capitalization 17 966 M 17 966 M -
EV / Sales 2022 10,4x
EV / Sales 2023 9,91x
Nbr of Employees -
Free-Float 47,2%
Chart ROYALTY PHARMA PLC
Duration : Period :
Royalty Pharma plc Technical Analysis Chart | RPRX | GB00BMVP7Y09 | MarketScreener
Technical analysis trends ROYALTY PHARMA PLC
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 11
Last Close Price 41,27 $
Average target price 52,50 $
Spread / Average Target 27,2%
EPS Revisions
Managers and Directors
Pablo Gerardo Legorreta Chairman & Chief Executive Officer
Terrance Patrick Coyne Chief Financial Officer & Executive Vice President
James F. Reddoch Chief Scientific Officer & Executive VP
Marshall Urist Executive Vice President-Research & Investments
Sara Klymkowsky Vice President-Research & Investments
Sector and Competitors
1st jan.Capi. (M$)
ROYALTY PHARMA PLC3.56%17 966
NOVO NORDISK A/S-3.80%1 677 391
JOHNSON & JOHNSON5.86%476 521
PFIZER, INC.-8.70%302 483
ELI LILLY AND COMPANY17.11%291 184
ROCHE HOLDING AG-13.00%281 098